Sionna Therapeutics, Inc. (SION)

Market Cap	1.75B +191.8%
Revenue (ttm)	n/a
Net Income	-85.57M
EPS	-1.92
Shares Out	45.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	117,635
Open	38.97
Previous Close	39.24
Day's Range	37.48 - 39.19
52-Week Range	12.42 - 48.45
Beta	n/a
Analysts	Strong Buy
Price Target	51.60 (+33.23%)
Earnings Date	May 12, 2026

About SION

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 7, 2025
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: SION
• Website: https://www.sionnatx.com

Analyst Summary

According to 11 analysts, the average rating for SION stock is "Strong Buy." The 12-month stock price target is $51.6, which is an increase of 33.23% from the latest price.

Price Target

$51.6

(33.23% upside)

Analyst Consensus: Strong Buy